Drug intelligence / Profile preview

anti-CD19 anti-CD20 bispecific CAR-T

Development stage: Unknown
Lead developer: Beijing DOING Biomedical Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

anti-CD19 anti-CD20 bispecific CAR-T is an autologous T-cell therapy engineered to express a bispecific Chimeric Antigen Receptor (CAR) targeting both CD19 and CD20 antigens. Developed by Beijing Doing Biomedical Co., Ltd., this investigational therapy is being evaluated for its safety, efficacy, and duration of response in patients with high-risk, relapsed CD19+ and CD20+ hematological malignancies.

Other names: anti-CD19 anti-CD20 Bispecific CAR-Tanti-CD-19 anti-CD20 Bispecific CAR-Tanti-CD 19 anti-CD20 Bispecific CAR-TCD19/CD20 bispecific CAR-Tanti-CD19/CD20 CAR-T cellsanti-CD19 and anti-CD20 bispecific chimeric receptor T cellsanti-CD-19 and anti-CD20 bispecific chimeric receptor T cellsanti-CD 19 and anti-CD20 bispecific chimeric receptor T cells

Targets

CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on anti-CD19 anti-CD20 bispecific CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD19 anti-CD20 bispecific CAR-T.

Explore the full profile